[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fKyx3Z-vBEQpU66gTuSBzj78NSIwhue4R6x3-oZZcRnA":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":35,"phaseBuckets":56,"rows":63},"Aristotle University Of Thessaloniki",[4],270,false,44,2,46573,5,201,[14,17,20,22,25,28,30,32],{"name":15,"count":16},"Glaucoma",11,{"name":18,"count":19},"Subfertility",8,{"name":21,"count":19},"Hypertension",{"name":23,"count":24},"Mild Cognitive Impairment",7,{"name":26,"count":27},"Coronary Artery Disease",6,{"name":29,"count":11},"Obesity",{"name":31,"count":11},"Cardiovascular Diseases",{"name":33,"count":34},"Healthy",4,[36,41,46,51],{"nctId":37,"briefTitle":38,"date":39,"intervention":40},"NCT05708300","Biomarkers of Response to Mepolizumab Treatment in Patients With Nasal Polyps With or Without Bronchial Asthma","2026-03-01","Mepolizumab 100 MG [Nucala]",{"nctId":42,"briefTitle":43,"date":44,"intervention":45},"NCT05493761","Effect of Anti-osteoporotic Medications on Nonalcoholic Fatty Liver Disease","2026-07","Denosumab",{"nctId":47,"briefTitle":48,"date":49,"intervention":50},"NCT06447519","Multiple-Visit RCT in Teeth With SAP: Interappointment Dressing or Not?","2026-09-12","Ca(OH)2 as intracanal medicament",{"nctId":52,"briefTitle":53,"date":54,"intervention":55},"NCT06523530","Effect of a GnRH Analog on Hepatic Steatosis","2027-04","Goserelin Acetate 3.6 mg inj, implant",[57,58,59,60,61,62],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[64,91,115,146,183,205,243,270,288,315,333,351,376,394,419,445,463,488,506,531,549,575,593,617,635,659,677,703,728,751,782,800,818,836,863,881,905,923,950,968,991,1009,1034,1052,1080,1098,1127,1145,1163,1188,1217,1235,1260,1278,1302,1329,1347,1373,1399,1417,1441,1465,1483,1509,1532,1556,1580,1607,1625,1650,1668,1686,1712,1737,1755,1779,1805,1827,1874,1906,1933,1957,1975,2003,2028,2054,2078,2107,2131,2161,2185,2203,2229,2247,2271,2295,2323,2349,2367,2392,2410],{"intervention":65,"totalTrials":66,"cells":67},"Alendronate Sodium",1,{"EARLY_PHASE1":68,"PHASE1":71,"PHASE2":73,"PHASE3":75,"PHASE4":77,"NA":89},{"trials":69,"activeCount":70},[],0,{"trials":72,"activeCount":70},[],{"trials":74,"activeCount":70},[],{"trials":76,"activeCount":70},[],{"trials":78,"activeCount":66,"soonestReadout":44},[79],{"nctId":42,"briefTitle":43,"status":80,"phases":81,"primaryCompletion":44,"completion":82,"start":83,"enrollment":84,"conditions":85,"interventions":88},"ACTIVE_NOT_RECRUITING",[61],"2026-09","2022-12-23",72,[86,87],"Nonalcoholic Fatty Liver","Osteoporosis, Postmenopausal",[45,65],{"trials":90,"activeCount":70},[],{"intervention":55,"totalTrials":66,"cells":92},{"EARLY_PHASE1":93,"PHASE1":95,"PHASE2":97,"PHASE3":99,"PHASE4":101,"NA":113},{"trials":94,"activeCount":70},[],{"trials":96,"activeCount":70},[],{"trials":98,"activeCount":70},[],{"trials":100,"activeCount":70},[],{"trials":102,"activeCount":66,"soonestReadout":54},[103],{"nctId":52,"briefTitle":53,"status":104,"phases":105,"primaryCompletion":54,"completion":106,"start":107,"enrollment":108,"conditions":109,"interventions":112},"RECRUITING",[61],"2027-10","2024-11-26",62,[110,86,111],"Metabolic Dysfunction-Associated Steatotic Liver Disease","Endometriosis",[55],{"trials":114,"activeCount":70},[],{"intervention":45,"totalTrials":9,"cells":116},{"EARLY_PHASE1":117,"PHASE1":119,"PHASE2":121,"PHASE3":123,"PHASE4":125,"NA":131},{"trials":118,"activeCount":70},[],{"trials":120,"activeCount":70},[],{"trials":122,"activeCount":70},[],{"trials":124,"activeCount":70},[],{"trials":126,"activeCount":66,"soonestReadout":44},[127],{"nctId":42,"briefTitle":43,"status":80,"phases":128,"primaryCompletion":44,"completion":82,"start":83,"enrollment":84,"conditions":129,"interventions":130},[61],[86,87],[45,65],{"trials":132,"activeCount":70},[133],{"nctId":134,"briefTitle":135,"status":136,"phases":137,"primaryCompletion":138,"completion":139,"start":140,"enrollment":141,"conditions":142,"interventions":144},"NCT01572545","Comparative Effect of Zoledronic Acid Versus Denosumab on Serum Sclerostin of Postmenopausal Women With Low Bone Mass","COMPLETED",[62],"2012-09","2013-01","2012-04",91,[143],"Postmenopausal Osteoporosis",[45,145],"Zoledronic acid",{"intervention":40,"totalTrials":9,"cells":147},{"EARLY_PHASE1":148,"PHASE1":150,"PHASE2":152,"PHASE3":154,"PHASE4":156,"NA":158},{"trials":149,"activeCount":70},[],{"trials":151,"activeCount":70},[],{"trials":153,"activeCount":70},[],{"trials":155,"activeCount":70},[],{"trials":157,"activeCount":70},[],{"trials":159,"activeCount":66,"soonestReadout":39},[160,169],{"nctId":37,"briefTitle":38,"status":104,"phases":161,"primaryCompletion":39,"completion":162,"start":163,"enrollment":164,"conditions":165,"interventions":168},[],"2027-03-01","2024-02-23",57,[166,167],"Chronic Rhinosinusitis With Nasal Polyps","Asthma",[40],{"nctId":170,"briefTitle":171,"status":172,"phases":173,"primaryCompletion":174,"completion":175,"start":176,"enrollment":177,"conditions":178,"interventions":182},"NCT04612556","Efficacy of Mepolizumab in Severe Asthmatics on a Long Term (MESILICO)","UNKNOWN",[],"2023-03-15","2025-03-15","2021-01-22",45,[179,180,181],"Asthma; Eosinophilic","Severe Asthma","Late-Onset Asthma",[40],{"intervention":50,"totalTrials":66,"cells":184},{"EARLY_PHASE1":185,"PHASE1":187,"PHASE2":189,"PHASE3":191,"PHASE4":193,"NA":195},{"trials":186,"activeCount":70},[],{"trials":188,"activeCount":70},[],{"trials":190,"activeCount":70},[],{"trials":192,"activeCount":70},[],{"trials":194,"activeCount":70},[],{"trials":196,"activeCount":66,"soonestReadout":49},[197],{"nctId":47,"briefTitle":48,"status":104,"phases":198,"primaryCompletion":49,"completion":49,"start":199,"enrollment":200,"conditions":201,"interventions":204},[62],"2024-09-12",110,[202,203],"Endodontically Treated Teeth","Calcium Hydroxide",[50],{"intervention":206,"totalTrials":9,"cells":207},"Nebivolol",{"EARLY_PHASE1":208,"PHASE1":210,"PHASE2":212,"PHASE3":225,"PHASE4":227,"NA":241},{"trials":209,"activeCount":70},[],{"trials":211,"activeCount":70},[],{"trials":213,"activeCount":70},[214],{"nctId":215,"briefTitle":216,"status":136,"phases":217,"primaryCompletion":218,"completion":218,"start":219,"enrollment":220,"conditions":221,"interventions":223},"NCT03655964","Effect of Olmesartan and Nebivolol on Ambulatory Blood Pressure and Arterial Stiffness in Acute Stage of Ischemic Stroke",[59],"2019-08-20","2018-08-20",60,[222],"Stroke, Ischemic",[224,206],"Olmesartan",{"trials":226,"activeCount":70},[],{"trials":228,"activeCount":70},[229],{"nctId":230,"briefTitle":231,"status":172,"phases":232,"primaryCompletion":233,"completion":234,"start":235,"enrollment":236,"conditions":237,"interventions":238},"NCT02057328","Comparative Study of the Effects of Telmisartan and Nebivolol",[61],"2015-01","2017-01","2010-12",80,[21],[239,240],"TELMISARTAN","NEBIVOLOL",{"trials":242,"activeCount":70},[],{"intervention":244,"totalTrials":66,"cells":245},"Microdrop administration [phenylephrine 1.67% + tropicamide 0.33% (drop volume: 6-7 μL)]",{"EARLY_PHASE1":246,"PHASE1":248,"PHASE2":250,"PHASE3":252,"PHASE4":254,"NA":268},{"trials":247,"activeCount":70},[],{"trials":249,"activeCount":70},[],{"trials":251,"activeCount":70},[],{"trials":253,"activeCount":70},[],{"trials":255,"activeCount":70},[256],{"nctId":257,"briefTitle":258,"status":136,"phases":259,"primaryCompletion":260,"completion":261,"start":262,"enrollment":263,"conditions":264,"interventions":266},"NCT04623684","Efficacy and Safety of Mydriatic Microdrops Compared With Standard Drops for Retinopathy of Prematurity (ROP) Screening: a Pilot Randomized Clinical Trial",[61],"2020-09-22","2020-09-29","2020-03-24",25,[265],"Retinopathy of Prematurity",[244,267],"Standard drop administration [phenylephrine 1.67% + tropicamide 0.33% (drop volume: 28-34 μL)]",{"trials":269,"activeCount":70},[],{"intervention":267,"totalTrials":66,"cells":271},{"EARLY_PHASE1":272,"PHASE1":274,"PHASE2":276,"PHASE3":278,"PHASE4":280,"NA":286},{"trials":273,"activeCount":70},[],{"trials":275,"activeCount":70},[],{"trials":277,"activeCount":70},[],{"trials":279,"activeCount":70},[],{"trials":281,"activeCount":70},[282],{"nctId":257,"briefTitle":258,"status":136,"phases":283,"primaryCompletion":260,"completion":261,"start":262,"enrollment":263,"conditions":284,"interventions":285},[61],[265],[244,267],{"trials":287,"activeCount":70},[],{"intervention":289,"totalTrials":66,"cells":290},"Drug: dorzolamide\u002Ftimolol",{"EARLY_PHASE1":291,"PHASE1":293,"PHASE2":295,"PHASE3":297,"PHASE4":299,"NA":313},{"trials":292,"activeCount":70},[],{"trials":294,"activeCount":70},[],{"trials":296,"activeCount":70},[],{"trials":298,"activeCount":70},[],{"trials":300,"activeCount":70},[301],{"nctId":302,"briefTitle":303,"status":136,"phases":304,"primaryCompletion":305,"completion":305,"start":306,"enrollment":307,"conditions":308,"interventions":310},"NCT00397241","24-hour Study of Dorzolamide\u002FTimolol and Latanoprost\u002FTimolol Fixed Combinations",[61],"2007-12","2006-09",33,[309],"Open-angle Glaucoma",[289,311,312],"Drug: latanoprost\u002Ftimolol","dorzolamide\u002Ftimolol and latanoprost",{"trials":314,"activeCount":70},[],{"intervention":311,"totalTrials":66,"cells":316},{"EARLY_PHASE1":317,"PHASE1":319,"PHASE2":321,"PHASE3":323,"PHASE4":325,"NA":331},{"trials":318,"activeCount":70},[],{"trials":320,"activeCount":70},[],{"trials":322,"activeCount":70},[],{"trials":324,"activeCount":70},[],{"trials":326,"activeCount":70},[327],{"nctId":302,"briefTitle":303,"status":136,"phases":328,"primaryCompletion":305,"completion":305,"start":306,"enrollment":307,"conditions":329,"interventions":330},[61],[309],[289,311,312],{"trials":332,"activeCount":70},[],{"intervention":312,"totalTrials":66,"cells":334},{"EARLY_PHASE1":335,"PHASE1":337,"PHASE2":339,"PHASE3":341,"PHASE4":343,"NA":349},{"trials":336,"activeCount":70},[],{"trials":338,"activeCount":70},[],{"trials":340,"activeCount":70},[],{"trials":342,"activeCount":70},[],{"trials":344,"activeCount":70},[345],{"nctId":302,"briefTitle":303,"status":136,"phases":346,"primaryCompletion":305,"completion":305,"start":306,"enrollment":307,"conditions":347,"interventions":348},[61],[309],[289,311,312],{"trials":350,"activeCount":70},[],{"intervention":352,"totalTrials":66,"cells":353},"Cannabidiol Oil",{"EARLY_PHASE1":354,"PHASE1":356,"PHASE2":358,"PHASE3":360,"PHASE4":362,"NA":374},{"trials":355,"activeCount":70},[],{"trials":357,"activeCount":70},[],{"trials":359,"activeCount":70},[],{"trials":361,"activeCount":70},[],{"trials":363,"activeCount":70},[364],{"nctId":365,"briefTitle":366,"status":172,"phases":367,"primaryCompletion":368,"completion":368,"start":369,"enrollment":370,"conditions":371,"interventions":372},"NCT05022186","The Effects of Cannabidiol and Homotaurine in Patients With Mild Cognitive Impairment",[61],"2022-12-20","2021-04-01",90,[23],[352,373],"Homotaurine",{"trials":375,"activeCount":70},[],{"intervention":373,"totalTrials":66,"cells":377},{"EARLY_PHASE1":378,"PHASE1":380,"PHASE2":382,"PHASE3":384,"PHASE4":386,"NA":392},{"trials":379,"activeCount":70},[],{"trials":381,"activeCount":70},[],{"trials":383,"activeCount":70},[],{"trials":385,"activeCount":70},[],{"trials":387,"activeCount":70},[388],{"nctId":365,"briefTitle":366,"status":172,"phases":389,"primaryCompletion":368,"completion":368,"start":369,"enrollment":370,"conditions":390,"interventions":391},[61],[23],[352,373],{"trials":393,"activeCount":70},[],{"intervention":395,"totalTrials":66,"cells":396},"Benralizumab 30 mg\u002Fml",{"EARLY_PHASE1":397,"PHASE1":399,"PHASE2":401,"PHASE3":403,"PHASE4":405,"NA":417},{"trials":398,"activeCount":70},[],{"trials":400,"activeCount":70},[],{"trials":402,"activeCount":70},[],{"trials":404,"activeCount":70},[],{"trials":406,"activeCount":70},[407],{"nctId":408,"briefTitle":409,"status":172,"phases":410,"primaryCompletion":411,"completion":412,"start":413,"enrollment":177,"conditions":414,"interventions":416},"NCT06288516","BenRalizumab Effect on Airway Remodeling in Severe asTHma",[61],"2025-12-31","2026-06-01","2024-03-01",[179,415],"Airway Remodeling",[395],{"trials":418,"activeCount":70},[],{"intervention":420,"totalTrials":66,"cells":421},"Microdrop administration of phenylephrine 1.67% and tropicamide 0.33%",{"EARLY_PHASE1":422,"PHASE1":424,"PHASE2":426,"PHASE3":428,"PHASE4":430,"NA":443},{"trials":423,"activeCount":70},[],{"trials":425,"activeCount":70},[],{"trials":427,"activeCount":70},[],{"trials":429,"activeCount":70},[],{"trials":431,"activeCount":70},[432],{"nctId":433,"briefTitle":434,"status":136,"phases":435,"primaryCompletion":436,"completion":437,"start":438,"enrollment":439,"conditions":440,"interventions":441},"NCT05043077","Efficacy and Safety of Mydriatic Microdrops for Retinopathy Of Prematurity Screening",[61],"2023-01-20","2023-01-23","2021-09-07",83,[265],[420,442],"Standard drop administration of phenylephrine 1.67% and tropicamide 0.33%",{"trials":444,"activeCount":70},[],{"intervention":442,"totalTrials":66,"cells":446},{"EARLY_PHASE1":447,"PHASE1":449,"PHASE2":451,"PHASE3":453,"PHASE4":455,"NA":461},{"trials":448,"activeCount":70},[],{"trials":450,"activeCount":70},[],{"trials":452,"activeCount":70},[],{"trials":454,"activeCount":70},[],{"trials":456,"activeCount":70},[457],{"nctId":433,"briefTitle":434,"status":136,"phases":458,"primaryCompletion":436,"completion":437,"start":438,"enrollment":439,"conditions":459,"interventions":460},[61],[265],[420,442],{"trials":462,"activeCount":70},[],{"intervention":464,"totalTrials":66,"cells":465},"Brimonidine\u002Ftimolol fixed combination drops added to travoprost",{"EARLY_PHASE1":466,"PHASE1":468,"PHASE2":470,"PHASE3":472,"PHASE4":474,"NA":486},{"trials":467,"activeCount":70},[],{"trials":469,"activeCount":70},[],{"trials":471,"activeCount":70},[],{"trials":473,"activeCount":70},[],{"trials":475,"activeCount":70},[476],{"nctId":477,"briefTitle":478,"status":136,"phases":479,"primaryCompletion":480,"completion":235,"start":481,"enrollment":482,"conditions":483,"interventions":484},"NCT00981786","24-Hour Intraocular Pressure With Brinzolamide\u002FTimolol Versus Brimonidine\u002FTimolol",[61],"2010-09","2009-08",51,[15],[464,485],"Brinzolamide\u002Ftimolol fixed combination drops added to travoprost",{"trials":487,"activeCount":70},[],{"intervention":485,"totalTrials":66,"cells":489},{"EARLY_PHASE1":490,"PHASE1":492,"PHASE2":494,"PHASE3":496,"PHASE4":498,"NA":504},{"trials":491,"activeCount":70},[],{"trials":493,"activeCount":70},[],{"trials":495,"activeCount":70},[],{"trials":497,"activeCount":70},[],{"trials":499,"activeCount":70},[500],{"nctId":477,"briefTitle":478,"status":136,"phases":501,"primaryCompletion":480,"completion":235,"start":481,"enrollment":482,"conditions":502,"interventions":503},[61],[15],[464,485],{"trials":505,"activeCount":70},[],{"intervention":507,"totalTrials":66,"cells":508},"treatment with dorzolamide\u002Ftimolol",{"EARLY_PHASE1":509,"PHASE1":511,"PHASE2":513,"PHASE3":515,"PHASE4":517,"NA":529},{"trials":510,"activeCount":70},[],{"trials":512,"activeCount":70},[],{"trials":514,"activeCount":70},[],{"trials":516,"activeCount":70},[],{"trials":518,"activeCount":70},[519],{"nctId":520,"briefTitle":521,"status":136,"phases":522,"primaryCompletion":523,"completion":523,"start":524,"enrollment":525,"conditions":526,"interventions":527},"NCT00972257","24-hr Intraocular Pressure Control With Dorzolamide\u002FTimolol vs the Brimonidine\u002FTimolol Fixed Combination",[61],"2009-09","2009-01",64,[15],[507,528],"treatment with brimonidine\u002Ftimolol",{"trials":530,"activeCount":70},[],{"intervention":528,"totalTrials":66,"cells":532},{"EARLY_PHASE1":533,"PHASE1":535,"PHASE2":537,"PHASE3":539,"PHASE4":541,"NA":547},{"trials":534,"activeCount":70},[],{"trials":536,"activeCount":70},[],{"trials":538,"activeCount":70},[],{"trials":540,"activeCount":70},[],{"trials":542,"activeCount":70},[543],{"nctId":520,"briefTitle":521,"status":136,"phases":544,"primaryCompletion":523,"completion":523,"start":524,"enrollment":525,"conditions":545,"interventions":546},[61],[15],[507,528],{"trials":548,"activeCount":70},[],{"intervention":550,"totalTrials":66,"cells":551},"Droperidol",{"EARLY_PHASE1":552,"PHASE1":554,"PHASE2":556,"PHASE3":558,"PHASE4":560,"NA":573},{"trials":553,"activeCount":70},[],{"trials":555,"activeCount":70},[],{"trials":557,"activeCount":70},[],{"trials":559,"activeCount":70},[],{"trials":561,"activeCount":70},[562],{"nctId":563,"briefTitle":564,"status":136,"phases":565,"primaryCompletion":566,"completion":566,"start":567,"enrollment":568,"conditions":569,"interventions":571},"NCT00702442","Role of Droperidol in Postoperative Vomiting",[61],"2011-07","2008-06",100,[570],"Vomiting",[550,572],"Saline solution",{"trials":574,"activeCount":70},[],{"intervention":572,"totalTrials":66,"cells":576},{"EARLY_PHASE1":577,"PHASE1":579,"PHASE2":581,"PHASE3":583,"PHASE4":585,"NA":591},{"trials":578,"activeCount":70},[],{"trials":580,"activeCount":70},[],{"trials":582,"activeCount":70},[],{"trials":584,"activeCount":70},[],{"trials":586,"activeCount":70},[587],{"nctId":563,"briefTitle":564,"status":136,"phases":588,"primaryCompletion":566,"completion":566,"start":567,"enrollment":568,"conditions":589,"interventions":590},[61],[570],[550,572],{"trials":592,"activeCount":70},[],{"intervention":594,"totalTrials":66,"cells":595},"Corifollitropin alfa",{"EARLY_PHASE1":596,"PHASE1":598,"PHASE2":600,"PHASE3":602,"PHASE4":604,"NA":615},{"trials":597,"activeCount":70},[],{"trials":599,"activeCount":70},[],{"trials":601,"activeCount":70},[],{"trials":603,"activeCount":70},[],{"trials":605,"activeCount":70},[606],{"nctId":607,"briefTitle":608,"status":136,"phases":609,"primaryCompletion":610,"start":611,"enrollment":236,"conditions":612,"interventions":613},"NCT02046655","Corifollitropin Alfa Compared to Daily rFSH in Poor Responders Undergoing ICSI",[61],"2014-03","2011-01",[18],[594,614],"rFSH",{"trials":616,"activeCount":70},[],{"intervention":614,"totalTrials":66,"cells":618},{"EARLY_PHASE1":619,"PHASE1":621,"PHASE2":623,"PHASE3":625,"PHASE4":627,"NA":633},{"trials":620,"activeCount":70},[],{"trials":622,"activeCount":70},[],{"trials":624,"activeCount":70},[],{"trials":626,"activeCount":70},[],{"trials":628,"activeCount":70},[629],{"nctId":607,"briefTitle":608,"status":136,"phases":630,"primaryCompletion":610,"start":611,"enrollment":236,"conditions":631,"interventions":632},[61],[18],[594,614],{"trials":634,"activeCount":70},[],{"intervention":636,"totalTrials":66,"cells":637},"Propofol",{"EARLY_PHASE1":638,"PHASE1":640,"PHASE2":642,"PHASE3":644,"PHASE4":646,"NA":657},{"trials":639,"activeCount":70},[],{"trials":641,"activeCount":70},[],{"trials":643,"activeCount":70},[],{"trials":645,"activeCount":70},[],{"trials":647,"activeCount":70},[648],{"nctId":649,"briefTitle":650,"status":136,"phases":651,"primaryCompletion":652,"completion":652,"start":524,"enrollment":653,"conditions":654,"interventions":655},"NCT02377778","Comparative Effect of Theipoental and Propofol in IVF Outcome",[61],"2013-03",180,[18],[636,656],"Thiopental",{"trials":658,"activeCount":70},[],{"intervention":656,"totalTrials":66,"cells":660},{"EARLY_PHASE1":661,"PHASE1":663,"PHASE2":665,"PHASE3":667,"PHASE4":669,"NA":675},{"trials":662,"activeCount":70},[],{"trials":664,"activeCount":70},[],{"trials":666,"activeCount":70},[],{"trials":668,"activeCount":70},[],{"trials":670,"activeCount":70},[671],{"nctId":649,"briefTitle":650,"status":136,"phases":672,"primaryCompletion":652,"completion":652,"start":524,"enrollment":653,"conditions":673,"interventions":674},[61],[18],[636,656],{"trials":676,"activeCount":70},[],{"intervention":678,"totalTrials":66,"cells":679},"Tetracycline slurry",{"EARLY_PHASE1":680,"PHASE1":682,"PHASE2":684,"PHASE3":686,"PHASE4":688,"NA":701},{"trials":681,"activeCount":70},[],{"trials":683,"activeCount":70},[],{"trials":685,"activeCount":70},[],{"trials":687,"activeCount":70},[],{"trials":689,"activeCount":70},[690],{"nctId":691,"briefTitle":692,"status":136,"phases":693,"primaryCompletion":694,"completion":694,"start":695,"enrollment":696,"conditions":697,"interventions":700},"NCT06695559","Non-surgical Treatment of Peri-implantitis Using Chitosan Brush and Tetracycline Slurry",[61],"2025-05-05","2024-02-05",40,[698,699],"Periimplantitis","Periimplant Diseases",[678],{"trials":702,"activeCount":70},[],{"intervention":704,"totalTrials":66,"cells":705},"Cetrorelix",{"EARLY_PHASE1":706,"PHASE1":708,"PHASE2":710,"PHASE3":712,"PHASE4":714,"NA":726},{"trials":707,"activeCount":70},[],{"trials":709,"activeCount":70},[],{"trials":711,"activeCount":70},[],{"trials":713,"activeCount":70},[],{"trials":715,"activeCount":70},[716],{"nctId":717,"briefTitle":718,"status":136,"phases":719,"primaryCompletion":720,"completion":721,"start":722,"enrollment":723,"conditions":724,"interventions":725},"NCT01005784","Fixed Versus Flexible Gonadotropin-releasing Hormone (GnRH) Antagonist Initiation",[61],"2008-01","2008-03","2005-06",146,[18],[704,704],{"trials":727,"activeCount":70},[],{"intervention":729,"totalTrials":66,"cells":730},"Travoprost\u002Ftimolol fixed combination, travoprost",{"EARLY_PHASE1":731,"PHASE1":733,"PHASE2":735,"PHASE3":737,"PHASE4":739,"NA":749},{"trials":732,"activeCount":70},[],{"trials":734,"activeCount":70},[],{"trials":736,"activeCount":70},[],{"trials":738,"activeCount":70},[],{"trials":740,"activeCount":70},[741],{"nctId":742,"briefTitle":743,"status":136,"phases":744,"primaryCompletion":720,"completion":720,"start":745,"enrollment":746,"conditions":747,"interventions":748},"NCT00444184","24-hour Intraocular Pressure Control With Travoprost\u002FTimolol Fixed Combination Versus Travoprost",[61],"2007-03",32,[15],[729],{"trials":750,"activeCount":70},[],{"intervention":752,"totalTrials":66,"cells":753},"Tramadol with ropivacaine",{"EARLY_PHASE1":754,"PHASE1":756,"PHASE2":758,"PHASE3":760,"PHASE4":762,"NA":780},{"trials":755,"activeCount":70},[],{"trials":757,"activeCount":70},[],{"trials":759,"activeCount":70},[],{"trials":761,"activeCount":70},[],{"trials":763,"activeCount":70},[764],{"nctId":765,"briefTitle":766,"status":136,"phases":767,"primaryCompletion":768,"completion":769,"start":770,"enrollment":84,"conditions":771,"interventions":776},"NCT04391855","Wound Infiltration With Tramadol, Dexmedetomidine, or Magnesium Plus Ropivacaine for Pain Relief After Spine Surgery",[61],"2022-11-08","2022-12-10","2020-05-10",[772,773,774,775],"Analgesia","Pain, Postoperative","Spinal Stenosis","Spinal Disease",[752,777,778,779],"Dexmedetomidine with ropivacaine","Magnesium with ropivacaine","Ropivacaine plus normal saline",{"trials":781,"activeCount":70},[],{"intervention":777,"totalTrials":66,"cells":783},{"EARLY_PHASE1":784,"PHASE1":786,"PHASE2":788,"PHASE3":790,"PHASE4":792,"NA":798},{"trials":785,"activeCount":70},[],{"trials":787,"activeCount":70},[],{"trials":789,"activeCount":70},[],{"trials":791,"activeCount":70},[],{"trials":793,"activeCount":70},[794],{"nctId":765,"briefTitle":766,"status":136,"phases":795,"primaryCompletion":768,"completion":769,"start":770,"enrollment":84,"conditions":796,"interventions":797},[61],[772,773,774,775],[752,777,778,779],{"trials":799,"activeCount":70},[],{"intervention":778,"totalTrials":66,"cells":801},{"EARLY_PHASE1":802,"PHASE1":804,"PHASE2":806,"PHASE3":808,"PHASE4":810,"NA":816},{"trials":803,"activeCount":70},[],{"trials":805,"activeCount":70},[],{"trials":807,"activeCount":70},[],{"trials":809,"activeCount":70},[],{"trials":811,"activeCount":70},[812],{"nctId":765,"briefTitle":766,"status":136,"phases":813,"primaryCompletion":768,"completion":769,"start":770,"enrollment":84,"conditions":814,"interventions":815},[61],[772,773,774,775],[752,777,778,779],{"trials":817,"activeCount":70},[],{"intervention":779,"totalTrials":66,"cells":819},{"EARLY_PHASE1":820,"PHASE1":822,"PHASE2":824,"PHASE3":826,"PHASE4":828,"NA":834},{"trials":821,"activeCount":70},[],{"trials":823,"activeCount":70},[],{"trials":825,"activeCount":70},[],{"trials":827,"activeCount":70},[],{"trials":829,"activeCount":70},[830],{"nctId":765,"briefTitle":766,"status":136,"phases":831,"primaryCompletion":768,"completion":769,"start":770,"enrollment":84,"conditions":832,"interventions":833},[61],[772,773,774,775],[752,777,778,779],{"trials":835,"activeCount":70},[],{"intervention":837,"totalTrials":66,"cells":838},"tafluprost",{"EARLY_PHASE1":839,"PHASE1":841,"PHASE2":843,"PHASE3":845,"PHASE4":847,"NA":861},{"trials":840,"activeCount":70},[],{"trials":842,"activeCount":70},[],{"trials":844,"activeCount":70},[],{"trials":846,"activeCount":70},[],{"trials":848,"activeCount":70},[849],{"nctId":850,"briefTitle":851,"status":136,"phases":852,"primaryCompletion":853,"completion":854,"start":855,"enrollment":856,"conditions":857,"interventions":859},"NCT02802137","24-hour Efficacy and Ocular Surface With Talfuprost and Triple Combined Therapy",[61],"2015-12","2016-01","2015-03",43,[15,858],"Ocular Surface Disease",[837,860],"tafluprost and dorzolamide\u002Ftimolol",{"trials":862,"activeCount":70},[],{"intervention":860,"totalTrials":66,"cells":864},{"EARLY_PHASE1":865,"PHASE1":867,"PHASE2":869,"PHASE3":871,"PHASE4":873,"NA":879},{"trials":866,"activeCount":70},[],{"trials":868,"activeCount":70},[],{"trials":870,"activeCount":70},[],{"trials":872,"activeCount":70},[],{"trials":874,"activeCount":70},[875],{"nctId":850,"briefTitle":851,"status":136,"phases":876,"primaryCompletion":853,"completion":854,"start":855,"enrollment":856,"conditions":877,"interventions":878},[61],[15,858],[837,860],{"trials":880,"activeCount":70},[],{"intervention":882,"totalTrials":66,"cells":883},"treatment with latanoprost\u002Ftimolol fixed combination",{"EARLY_PHASE1":884,"PHASE1":886,"PHASE2":888,"PHASE3":890,"PHASE4":892,"NA":903},{"trials":885,"activeCount":70},[],{"trials":887,"activeCount":70},[],{"trials":889,"activeCount":70},[],{"trials":891,"activeCount":70},[],{"trials":893,"activeCount":70},[894],{"nctId":895,"briefTitle":896,"status":136,"phases":897,"primaryCompletion":898,"completion":898,"start":899,"enrollment":696,"conditions":900,"interventions":901},"NCT00757835","24-hr IOP With Travoprost\u002FTimolol Compared With Latanoprost\u002FTimolol in XFG",[61],"2009-03","2008-05",[15],[882,902],"latanoprost\u002Ftimolol fixed combination drops",{"trials":904,"activeCount":70},[],{"intervention":902,"totalTrials":66,"cells":906},{"EARLY_PHASE1":907,"PHASE1":909,"PHASE2":911,"PHASE3":913,"PHASE4":915,"NA":921},{"trials":908,"activeCount":70},[],{"trials":910,"activeCount":70},[],{"trials":912,"activeCount":70},[],{"trials":914,"activeCount":70},[],{"trials":916,"activeCount":70},[917],{"nctId":895,"briefTitle":896,"status":136,"phases":918,"primaryCompletion":898,"completion":898,"start":899,"enrollment":696,"conditions":919,"interventions":920},[61],[15],[882,902],{"trials":922,"activeCount":70},[],{"intervention":924,"totalTrials":66,"cells":925},"Magnesium Sulfate",{"EARLY_PHASE1":926,"PHASE1":928,"PHASE2":930,"PHASE3":932,"PHASE4":934,"NA":948},{"trials":927,"activeCount":70},[],{"trials":929,"activeCount":70},[],{"trials":931,"activeCount":70},[],{"trials":933,"activeCount":70},[],{"trials":935,"activeCount":70},[936],{"nctId":937,"briefTitle":938,"status":136,"phases":939,"primaryCompletion":940,"completion":941,"start":942,"enrollment":943,"conditions":944,"interventions":946},"NCT04161729","Effects of Intraoperative Magnesium Sulfate on Perioperative Pain Relief After Spine Surgery",[61],"2020-05-03","2020-05-05","2020-01-28",74,[772,773,945],"Spine Disease",[924,947],"Isotonic saline 0.9%",{"trials":949,"activeCount":70},[],{"intervention":947,"totalTrials":66,"cells":951},{"EARLY_PHASE1":952,"PHASE1":954,"PHASE2":956,"PHASE3":958,"PHASE4":960,"NA":966},{"trials":953,"activeCount":70},[],{"trials":955,"activeCount":70},[],{"trials":957,"activeCount":70},[],{"trials":959,"activeCount":70},[],{"trials":961,"activeCount":70},[962],{"nctId":937,"briefTitle":938,"status":136,"phases":963,"primaryCompletion":940,"completion":941,"start":942,"enrollment":943,"conditions":964,"interventions":965},[61],[772,773,945],[924,947],{"trials":967,"activeCount":70},[],{"intervention":969,"totalTrials":66,"cells":970},"Drug: bimatoprost\u002Ftimolol fixed combination AM",{"EARLY_PHASE1":971,"PHASE1":973,"PHASE2":975,"PHASE3":977,"PHASE4":979,"NA":989},{"trials":972,"activeCount":70},[],{"trials":974,"activeCount":70},[],{"trials":976,"activeCount":70},[],{"trials":978,"activeCount":70},[],{"trials":980,"activeCount":70},[981],{"nctId":982,"briefTitle":983,"status":136,"phases":984,"primaryCompletion":899,"completion":985,"start":745,"enrollment":220,"conditions":986,"interventions":987},"NCT00486486","24-hour Intraocular Pressure (IOP) Control With the Bimatoprost\u002FTimolol Fixed Combination",[61],"2008-07",[15],[969,988],"Bimatoprost\u002Ftimolol fixed combination dosed PM",{"trials":990,"activeCount":70},[],{"intervention":988,"totalTrials":66,"cells":992},{"EARLY_PHASE1":993,"PHASE1":995,"PHASE2":997,"PHASE3":999,"PHASE4":1001,"NA":1007},{"trials":994,"activeCount":70},[],{"trials":996,"activeCount":70},[],{"trials":998,"activeCount":70},[],{"trials":1000,"activeCount":70},[],{"trials":1002,"activeCount":70},[1003],{"nctId":982,"briefTitle":983,"status":136,"phases":1004,"primaryCompletion":899,"completion":985,"start":745,"enrollment":220,"conditions":1005,"interventions":1006},[61],[15],[969,988],{"trials":1008,"activeCount":70},[],{"intervention":1010,"totalTrials":66,"cells":1011},"Travoprost\u002Ftimolol therapy",{"EARLY_PHASE1":1012,"PHASE1":1014,"PHASE2":1016,"PHASE3":1018,"PHASE4":1020,"NA":1032},{"trials":1013,"activeCount":70},[],{"trials":1015,"activeCount":70},[],{"trials":1017,"activeCount":70},[],{"trials":1019,"activeCount":70},[],{"trials":1021,"activeCount":70},[1022],{"nctId":1023,"briefTitle":1024,"status":136,"phases":1025,"primaryCompletion":1026,"completion":139,"start":1027,"enrollment":1028,"conditions":1029,"interventions":1030},"NCT01779284","Travoprost\u002FTimolol vs Latanoprost\u002FTimolol Fixed Combination Therapy",[61],"2012-12","2012-01",42,[15],[1010,1031],"Latanoprost\u002FTimolol therapy",{"trials":1033,"activeCount":70},[],{"intervention":1031,"totalTrials":66,"cells":1035},{"EARLY_PHASE1":1036,"PHASE1":1038,"PHASE2":1040,"PHASE3":1042,"PHASE4":1044,"NA":1050},{"trials":1037,"activeCount":70},[],{"trials":1039,"activeCount":70},[],{"trials":1041,"activeCount":70},[],{"trials":1043,"activeCount":70},[],{"trials":1045,"activeCount":70},[1046],{"nctId":1023,"briefTitle":1024,"status":136,"phases":1047,"primaryCompletion":1026,"completion":139,"start":1027,"enrollment":1028,"conditions":1048,"interventions":1049},[61],[15],[1010,1031],{"trials":1051,"activeCount":70},[],{"intervention":1053,"totalTrials":66,"cells":1054},"Sevoflurane inhalant product",{"EARLY_PHASE1":1055,"PHASE1":1057,"PHASE2":1059,"PHASE3":1061,"PHASE4":1063,"NA":1078},{"trials":1056,"activeCount":70},[],{"trials":1058,"activeCount":70},[],{"trials":1060,"activeCount":70},[],{"trials":1062,"activeCount":70},[],{"trials":1064,"activeCount":70},[1065],{"nctId":1066,"briefTitle":1067,"status":136,"phases":1068,"primaryCompletion":1069,"completion":1070,"start":1071,"enrollment":220,"conditions":1072,"interventions":1076},"NCT04802122","Induction of Anesthesia With Sevoflurane Preserving Spontaneous Breathing: Cardiorespiratory Effects.",[61],"2021-07-13","2021-07-14","2021-05-24",[1073,1074,1075],"Anesthesia Intubation Complication","Cardiovascular Complication","Intubation",[1053,1077],"Propofol Fresenius",{"trials":1079,"activeCount":70},[],{"intervention":1077,"totalTrials":66,"cells":1081},{"EARLY_PHASE1":1082,"PHASE1":1084,"PHASE2":1086,"PHASE3":1088,"PHASE4":1090,"NA":1096},{"trials":1083,"activeCount":70},[],{"trials":1085,"activeCount":70},[],{"trials":1087,"activeCount":70},[],{"trials":1089,"activeCount":70},[],{"trials":1091,"activeCount":70},[1092],{"nctId":1066,"briefTitle":1067,"status":136,"phases":1093,"primaryCompletion":1069,"completion":1070,"start":1071,"enrollment":220,"conditions":1094,"interventions":1095},[61],[1073,1074,1075],[1053,1077],{"trials":1097,"activeCount":70},[],{"intervention":1099,"totalTrials":66,"cells":1100},"Ropivacaine 10%",{"EARLY_PHASE1":1101,"PHASE1":1103,"PHASE2":1105,"PHASE3":1107,"PHASE4":1109,"NA":1125},{"trials":1102,"activeCount":70},[],{"trials":1104,"activeCount":70},[],{"trials":1106,"activeCount":70},[],{"trials":1108,"activeCount":70},[],{"trials":1110,"activeCount":70},[1111],{"nctId":1112,"briefTitle":1113,"status":136,"phases":1114,"primaryCompletion":1115,"completion":1115,"start":1116,"enrollment":1117,"conditions":1118,"interventions":1123},"NCT05294393","Ropivacaine Plus Magnesium Sulphate Infiltration",[61],"2024-01-18","2022-01-19",68,[1119,1120,1121,1122],"Thyroid Diseases","Parathyroid Diseases","Postoperative Pain","Anesthesia, Local",[1099,1124],"Ropivacaine 10% plus magnesium sulphate 10mg\u002Fkg",{"trials":1126,"activeCount":70},[],{"intervention":1124,"totalTrials":66,"cells":1128},{"EARLY_PHASE1":1129,"PHASE1":1131,"PHASE2":1133,"PHASE3":1135,"PHASE4":1137,"NA":1143},{"trials":1130,"activeCount":70},[],{"trials":1132,"activeCount":70},[],{"trials":1134,"activeCount":70},[],{"trials":1136,"activeCount":70},[],{"trials":1138,"activeCount":70},[1139],{"nctId":1112,"briefTitle":1113,"status":136,"phases":1140,"primaryCompletion":1115,"completion":1115,"start":1116,"enrollment":1117,"conditions":1141,"interventions":1142},[61],[1119,1120,1121,1122],[1099,1124],{"trials":1144,"activeCount":70},[],{"intervention":239,"totalTrials":66,"cells":1146},{"EARLY_PHASE1":1147,"PHASE1":1149,"PHASE2":1151,"PHASE3":1153,"PHASE4":1155,"NA":1161},{"trials":1148,"activeCount":70},[],{"trials":1150,"activeCount":70},[],{"trials":1152,"activeCount":70},[],{"trials":1154,"activeCount":70},[],{"trials":1156,"activeCount":70},[1157],{"nctId":230,"briefTitle":231,"status":172,"phases":1158,"primaryCompletion":233,"completion":234,"start":235,"enrollment":236,"conditions":1159,"interventions":1160},[61],[21],[239,240],{"trials":1162,"activeCount":70},[],{"intervention":1164,"totalTrials":66,"cells":1165},"Latanoprost",{"EARLY_PHASE1":1166,"PHASE1":1168,"PHASE2":1170,"PHASE3":1172,"PHASE4":1174,"NA":1186},{"trials":1167,"activeCount":70},[],{"trials":1169,"activeCount":70},[],{"trials":1171,"activeCount":70},[],{"trials":1173,"activeCount":70},[],{"trials":1175,"activeCount":70},[1176],{"nctId":1177,"briefTitle":1178,"status":136,"phases":1179,"primaryCompletion":1180,"completion":1180,"start":523,"enrollment":1181,"conditions":1182,"interventions":1185},"NCT00941525","Central Corneal Thickness and 24-hour Fluctuation of Intraocular Pressure",[61],"2014-07",174,[1183,1184],"Open Angle Glaucoma","Ocular Hypertension",[1164],{"trials":1187,"activeCount":70},[],{"intervention":1189,"totalTrials":66,"cells":1190},"Mannitol",{"EARLY_PHASE1":1191,"PHASE1":1193,"PHASE2":1195,"PHASE3":1197,"PHASE4":1199,"NA":1215},{"trials":1192,"activeCount":70},[],{"trials":1194,"activeCount":70},[],{"trials":1196,"activeCount":70},[],{"trials":1198,"activeCount":70},[],{"trials":1200,"activeCount":70},[1201],{"nctId":1202,"briefTitle":1203,"status":136,"phases":1204,"primaryCompletion":1205,"completion":1206,"start":1207,"enrollment":1208,"conditions":1209,"interventions":1213},"NCT03573999","Effect of Mannitol 20% Versus Hypertonic Saline 7.5% in Brain Metabolism and Oxygenation",[61],"2019-10-31","2019-12-20","2018-06-29",54,[1210,1211,1212],"Brain Edema","Metabolic Disturbance","Electrolyte and Fluid Balance Conditions",[1189,1214],"NaCl 7.5%",{"trials":1216,"activeCount":70},[],{"intervention":1214,"totalTrials":66,"cells":1218},{"EARLY_PHASE1":1219,"PHASE1":1221,"PHASE2":1223,"PHASE3":1225,"PHASE4":1227,"NA":1233},{"trials":1220,"activeCount":70},[],{"trials":1222,"activeCount":70},[],{"trials":1224,"activeCount":70},[],{"trials":1226,"activeCount":70},[],{"trials":1228,"activeCount":70},[1229],{"nctId":1202,"briefTitle":1203,"status":136,"phases":1230,"primaryCompletion":1205,"completion":1206,"start":1207,"enrollment":1208,"conditions":1231,"interventions":1232},[61],[1210,1211,1212],[1189,1214],{"trials":1234,"activeCount":70},[],{"intervention":1236,"totalTrials":66,"cells":1237},"Bimatoprost\u002FTimolol, 24-hour intraocular pressure monitoring",{"EARLY_PHASE1":1238,"PHASE1":1240,"PHASE2":1242,"PHASE3":1244,"PHASE4":1246,"NA":1258},{"trials":1239,"activeCount":70},[],{"trials":1241,"activeCount":70},[],{"trials":1243,"activeCount":70},[],{"trials":1245,"activeCount":70},[],{"trials":1247,"activeCount":70},[1248],{"nctId":1249,"briefTitle":1250,"status":136,"phases":1251,"primaryCompletion":1252,"completion":1252,"start":1253,"enrollment":1254,"conditions":1255,"interventions":1256},"NCT01448837","24-Hour Intraocular Pressure Control With Bimatoprost\u002FTimolol Versus Latanoprost as First Choice",[61],"2011-03","2010-04",37,[15],[1236,1257],"Latanoprost, 24-hour intraocular pressure monitoring",{"trials":1259,"activeCount":70},[],{"intervention":1257,"totalTrials":66,"cells":1261},{"EARLY_PHASE1":1262,"PHASE1":1264,"PHASE2":1266,"PHASE3":1268,"PHASE4":1270,"NA":1276},{"trials":1263,"activeCount":70},[],{"trials":1265,"activeCount":70},[],{"trials":1267,"activeCount":70},[],{"trials":1269,"activeCount":70},[],{"trials":1271,"activeCount":70},[1272],{"nctId":1249,"briefTitle":1250,"status":136,"phases":1273,"primaryCompletion":1252,"completion":1252,"start":1253,"enrollment":1254,"conditions":1274,"interventions":1275},[61],[15],[1236,1257],{"trials":1277,"activeCount":70},[],{"intervention":1279,"totalTrials":66,"cells":1280},"Quinapril",{"EARLY_PHASE1":1281,"PHASE1":1283,"PHASE2":1285,"PHASE3":1287,"PHASE4":1289,"NA":1300},{"trials":1282,"activeCount":70},[],{"trials":1284,"activeCount":70},[],{"trials":1286,"activeCount":70},[],{"trials":1288,"activeCount":70},[],{"trials":1290,"activeCount":70},[1291],{"nctId":1292,"briefTitle":1293,"status":136,"phases":1294,"primaryCompletion":1295,"start":1296,"conditions":1297,"interventions":1299},"NCT03031834","Efficacy of Administration of ACE-Inhibition on Autonomic and Peripheral Neuropathy in Patients With Diabetes Mellitus",[61],"2001-05","1999-01",[1298],"Diabetic Autonomic Neuropathy",[1279],{"trials":1301,"activeCount":70},[],{"intervention":1303,"totalTrials":66,"cells":1304},"timolol maleate 0.5%",{"EARLY_PHASE1":1305,"PHASE1":1307,"PHASE2":1309,"PHASE3":1311,"PHASE4":1313,"NA":1327},{"trials":1306,"activeCount":70},[],{"trials":1308,"activeCount":70},[],{"trials":1310,"activeCount":70},[],{"trials":1312,"activeCount":70},[],{"trials":1314,"activeCount":70},[1315],{"nctId":1316,"briefTitle":1317,"status":136,"phases":1318,"primaryCompletion":1319,"completion":1320,"start":1321,"enrollment":1322,"conditions":1323,"interventions":1325},"NCT00330577","24-Hour Intraocular Pressure (IOP) And Blood Pressure Control In Glaucoma And Ocular Hypertension Patients",[61],"2007-04","2007-07","2006-04",30,[1324,1184],"Primary Open Angle Glaucoma",[1303,1326],"latanoprost\u002Ftimolol fixed combination",{"trials":1328,"activeCount":70},[],{"intervention":1326,"totalTrials":66,"cells":1330},{"EARLY_PHASE1":1331,"PHASE1":1333,"PHASE2":1335,"PHASE3":1337,"PHASE4":1339,"NA":1345},{"trials":1332,"activeCount":70},[],{"trials":1334,"activeCount":70},[],{"trials":1336,"activeCount":70},[],{"trials":1338,"activeCount":70},[],{"trials":1340,"activeCount":70},[1341],{"nctId":1316,"briefTitle":1317,"status":136,"phases":1342,"primaryCompletion":1319,"completion":1320,"start":1321,"enrollment":1322,"conditions":1343,"interventions":1344},[61],[1324,1184],[1303,1326],{"trials":1346,"activeCount":70},[],{"intervention":1348,"totalTrials":66,"cells":1349},"Anti-diabetic medications",{"EARLY_PHASE1":1350,"PHASE1":1352,"PHASE2":1354,"PHASE3":1356,"PHASE4":1358,"NA":1371},{"trials":1351,"activeCount":70},[],{"trials":1353,"activeCount":70},[],{"trials":1355,"activeCount":70},[],{"trials":1357,"activeCount":70},[],{"trials":1359,"activeCount":70},[1360],{"nctId":1361,"briefTitle":1362,"status":136,"phases":1363,"primaryCompletion":1364,"completion":567,"start":1365,"enrollment":568,"conditions":1366,"interventions":1368},"NCT00373178","Metabolic Effects of Treatment in Patients With Recently Diagnosed Type 2 Diabetes",[61],"2007-01","2005-01",[1367],"Type 2 Diabetes Mellitus",[1369,1370,1348],"rosiglitazone","metformin",{"trials":1372,"activeCount":70},[],{"intervention":1374,"totalTrials":66,"cells":1375},"Orlistat",{"EARLY_PHASE1":1376,"PHASE1":1378,"PHASE2":1380,"PHASE3":1382,"PHASE4":1384,"NA":1397},{"trials":1377,"activeCount":70},[],{"trials":1379,"activeCount":70},[],{"trials":1381,"activeCount":70},[],{"trials":1383,"activeCount":70},[],{"trials":1385,"activeCount":70},[1386],{"nctId":1387,"briefTitle":1388,"status":172,"phases":1389,"primaryCompletion":1390,"completion":1026,"start":1391,"enrollment":1392,"conditions":1393,"interventions":1395},"NCT01475019","The Effect of Weight Loss on Anti-Müllerian Hormone Levels in Women With Polycystic Ovary Syndrome (PCOS)",[61],"2010-01","2004-01",200,[29,1394],"Polycystic Ovaries Syndrome",[1374,1396],"Sibutramine",{"trials":1398,"activeCount":70},[],{"intervention":1396,"totalTrials":66,"cells":1400},{"EARLY_PHASE1":1401,"PHASE1":1403,"PHASE2":1405,"PHASE3":1407,"PHASE4":1409,"NA":1415},{"trials":1402,"activeCount":70},[],{"trials":1404,"activeCount":70},[],{"trials":1406,"activeCount":70},[],{"trials":1408,"activeCount":70},[],{"trials":1410,"activeCount":70},[1411],{"nctId":1387,"briefTitle":1388,"status":172,"phases":1412,"primaryCompletion":1390,"completion":1026,"start":1391,"enrollment":1392,"conditions":1413,"interventions":1414},[61],[29,1394],[1374,1396],{"trials":1416,"activeCount":70},[],{"intervention":1418,"totalTrials":66,"cells":1419},"Tafluprost\u002Ftimolol fixed combination",{"EARLY_PHASE1":1420,"PHASE1":1422,"PHASE2":1424,"PHASE3":1426,"PHASE4":1428,"NA":1439},{"trials":1421,"activeCount":70},[],{"trials":1423,"activeCount":70},[],{"trials":1425,"activeCount":70},[],{"trials":1427,"activeCount":70},[],{"trials":1429,"activeCount":70},[1430],{"nctId":1431,"briefTitle":1432,"status":136,"phases":1433,"primaryCompletion":1434,"completion":1435,"start":234,"enrollment":1028,"conditions":1436,"interventions":1438},"NCT03612817","Preservative-free Tafluprost\u002FTimolol Fixed Combination: Morning vs Evening Dosing",[61],"2018-04","2018-07",[1437],"Glaucoma, Open-Angle",[1418],{"trials":1440,"activeCount":70},[],{"intervention":1442,"totalTrials":66,"cells":1443},"Irbesartan",{"EARLY_PHASE1":1444,"PHASE1":1446,"PHASE2":1448,"PHASE3":1450,"PHASE4":1452,"NA":1463},{"trials":1445,"activeCount":70},[],{"trials":1447,"activeCount":70},[],{"trials":1449,"activeCount":70},[],{"trials":1451,"activeCount":70},[],{"trials":1453,"activeCount":70},[1454],{"nctId":1455,"briefTitle":1456,"status":1457,"phases":1458,"primaryCompletion":139,"completion":1459,"start":1027,"enrollment":70,"conditions":1460,"interventions":1461},"NCT00987662","Irbesartan Versus Amlodipine: The OBI Study","WITHDRAWN",[61],"2014-01",[29,21],[1442,1462],"Amlodipine",{"trials":1464,"activeCount":70},[],{"intervention":1462,"totalTrials":66,"cells":1466},{"EARLY_PHASE1":1467,"PHASE1":1469,"PHASE2":1471,"PHASE3":1473,"PHASE4":1475,"NA":1481},{"trials":1468,"activeCount":70},[],{"trials":1470,"activeCount":70},[],{"trials":1472,"activeCount":70},[],{"trials":1474,"activeCount":70},[],{"trials":1476,"activeCount":70},[1477],{"nctId":1455,"briefTitle":1456,"status":1457,"phases":1478,"primaryCompletion":139,"completion":1459,"start":1027,"enrollment":70,"conditions":1479,"interventions":1480},[61],[29,21],[1442,1462],{"trials":1482,"activeCount":70},[],{"intervention":1484,"totalTrials":66,"cells":1485},"empagliflozin",{"EARLY_PHASE1":1486,"PHASE1":1488,"PHASE2":1490,"PHASE3":1492,"PHASE4":1494,"NA":1507},{"trials":1487,"activeCount":70},[],{"trials":1489,"activeCount":70},[],{"trials":1491,"activeCount":70},[],{"trials":1493,"activeCount":70},[],{"trials":1495,"activeCount":70},[1496],{"nctId":1497,"briefTitle":1498,"status":172,"phases":1499,"primaryCompletion":1500,"completion":1501,"start":854,"enrollment":1502,"conditions":1503,"interventions":1505},"NCT01001962","Double Blind Placebo Study of JARDIANCE® (Empagliflozin) in Prehypertensives Type II Diabetics",[61],"2019-01","2020-01",1054,[21,1504],"Type II Diabetes",[1484,1506],"Metformin",{"trials":1508,"activeCount":70},[],{"intervention":1510,"totalTrials":66,"cells":1511},"Moxonidine",{"EARLY_PHASE1":1512,"PHASE1":1514,"PHASE2":1516,"PHASE3":1518,"PHASE4":1520,"NA":1530},{"trials":1513,"activeCount":70},[],{"trials":1515,"activeCount":70},[],{"trials":1517,"activeCount":70},[],{"trials":1519,"activeCount":70},[],{"trials":1521,"activeCount":70},[1522],{"nctId":1523,"briefTitle":1524,"status":136,"phases":1525,"primaryCompletion":1526,"completion":1526,"start":1527,"enrollment":370,"conditions":1528,"interventions":1529},"NCT05147753","Moxonidine Effects on Neuropeptide Y",[61],"2014-06-30","2010-01-11",[29,21],[1510],{"trials":1531,"activeCount":70},[],{"intervention":1533,"totalTrials":66,"cells":1534},"travoprost\u002Ftimolol fixed combination",{"EARLY_PHASE1":1535,"PHASE1":1537,"PHASE2":1539,"PHASE3":1541,"PHASE4":1552,"NA":1554},{"trials":1536,"activeCount":70},[],{"trials":1538,"activeCount":70},[],{"trials":1540,"activeCount":70},[],{"trials":1542,"activeCount":70},[1543],{"nctId":1544,"briefTitle":1545,"status":136,"phases":1546,"primaryCompletion":1364,"completion":1547,"start":1548,"enrollment":746,"conditions":1549,"interventions":1551},"NCT00331240","24-Hour Intraocular Pressure (IOP) Control With Travoprost\u002FTimolol Fixed Combination",[60],"2007-02","2006-03",[1324,1550],"Exfoliation Syndrome",[1533],{"trials":1553,"activeCount":70},[],{"trials":1555,"activeCount":70},[],{"intervention":1557,"totalTrials":66,"cells":1558},"Testosterone",{"EARLY_PHASE1":1559,"PHASE1":1561,"PHASE2":1563,"PHASE3":1565,"PHASE4":1576,"NA":1578},{"trials":1560,"activeCount":70},[],{"trials":1562,"activeCount":70},[],{"trials":1564,"activeCount":70},[],{"trials":1566,"activeCount":70},[1567],{"nctId":1568,"briefTitle":1569,"status":136,"phases":1570,"primaryCompletion":1571,"completion":1571,"start":1572,"enrollment":1573,"conditions":1574,"interventions":1575},"NCT01961336","Transdermal Testosterone Pretreatment in Poor Responders Undergoing IVF",[60],"2015-06","2013-10",50,[18],[1557],{"trials":1577,"activeCount":70},[],{"trials":1579,"activeCount":70},[],{"intervention":1581,"totalTrials":66,"cells":1582},"N-acetylcysteine",{"EARLY_PHASE1":1583,"PHASE1":1585,"PHASE2":1587,"PHASE3":1601,"PHASE4":1603,"NA":1605},{"trials":1584,"activeCount":70},[],{"trials":1586,"activeCount":70},[],{"trials":1588,"activeCount":70},[1589],{"nctId":1590,"briefTitle":1591,"status":136,"phases":1592,"primaryCompletion":1593,"completion":1594,"start":1595,"enrollment":1596,"conditions":1597,"interventions":1599},"NCT03121222","The Effects of N-acetylcysteine on Performance and Redox Homeostasis",[59],"2016-02-15","2016-09-12","2015-11-01",36,[1598],"Glutathione Metabolism Anemias",[1581,1600],"Lactose",{"trials":1602,"activeCount":70},[],{"trials":1604,"activeCount":70},[],{"trials":1606,"activeCount":70},[],{"intervention":1600,"totalTrials":66,"cells":1608},{"EARLY_PHASE1":1609,"PHASE1":1611,"PHASE2":1613,"PHASE3":1619,"PHASE4":1621,"NA":1623},{"trials":1610,"activeCount":70},[],{"trials":1612,"activeCount":70},[],{"trials":1614,"activeCount":70},[1615],{"nctId":1590,"briefTitle":1591,"status":136,"phases":1616,"primaryCompletion":1593,"completion":1594,"start":1595,"enrollment":1596,"conditions":1617,"interventions":1618},[59],[1598],[1581,1600],{"trials":1620,"activeCount":70},[],{"trials":1622,"activeCount":70},[],{"trials":1624,"activeCount":70},[],{"intervention":1626,"totalTrials":66,"cells":1627},"0.1 mg triptorelin",{"EARLY_PHASE1":1628,"PHASE1":1630,"PHASE2":1632,"PHASE3":1644,"PHASE4":1646,"NA":1648},{"trials":1629,"activeCount":70},[],{"trials":1631,"activeCount":70},[],{"trials":1633,"activeCount":70},[1634],{"nctId":1635,"briefTitle":1636,"status":172,"phases":1637,"primaryCompletion":1638,"completion":1638,"start":1639,"enrollment":370,"conditions":1640,"interventions":1641},"NCT01973842","Evaluation of the Optimal Dose of GnRH Agonist for Triggering Final Oocyte Maturation in High Risk OHSS Patients",[59],"2016-07","2014-02",[18],[1626,1642,1643],"0.2 mg triptorelin","0.4 mg triptorelin",{"trials":1645,"activeCount":70},[],{"trials":1647,"activeCount":70},[],{"trials":1649,"activeCount":70},[],{"intervention":1642,"totalTrials":66,"cells":1651},{"EARLY_PHASE1":1652,"PHASE1":1654,"PHASE2":1656,"PHASE3":1662,"PHASE4":1664,"NA":1666},{"trials":1653,"activeCount":70},[],{"trials":1655,"activeCount":70},[],{"trials":1657,"activeCount":70},[1658],{"nctId":1635,"briefTitle":1636,"status":172,"phases":1659,"primaryCompletion":1638,"completion":1638,"start":1639,"enrollment":370,"conditions":1660,"interventions":1661},[59],[18],[1626,1642,1643],{"trials":1663,"activeCount":70},[],{"trials":1665,"activeCount":70},[],{"trials":1667,"activeCount":70},[],{"intervention":1643,"totalTrials":66,"cells":1669},{"EARLY_PHASE1":1670,"PHASE1":1672,"PHASE2":1674,"PHASE3":1680,"PHASE4":1682,"NA":1684},{"trials":1671,"activeCount":70},[],{"trials":1673,"activeCount":70},[],{"trials":1675,"activeCount":70},[1676],{"nctId":1635,"briefTitle":1636,"status":172,"phases":1677,"primaryCompletion":1638,"completion":1638,"start":1639,"enrollment":370,"conditions":1678,"interventions":1679},[59],[18],[1626,1642,1643],{"trials":1681,"activeCount":70},[],{"trials":1683,"activeCount":70},[],{"trials":1685,"activeCount":70},[],{"intervention":1687,"totalTrials":66,"cells":1688},"Biocomplex: aBM-MSCs\u002Ffibrin glue\u002Fcollagen fleece",{"EARLY_PHASE1":1689,"PHASE1":1691,"PHASE2":1693,"PHASE3":1706,"PHASE4":1708,"NA":1710},{"trials":1690,"activeCount":70},[],{"trials":1692,"activeCount":70},[],{"trials":1694,"activeCount":70},[1695],{"nctId":1696,"briefTitle":1697,"status":136,"phases":1698,"primaryCompletion":1699,"completion":1700,"start":1701,"enrollment":1702,"conditions":1703,"interventions":1705},"NCT03070275","Dental Implant Placement in Adjunction With Autologous Alveolar Bone-Marrow Derived Mesenchymal Stem Cells (aBM-MSCs)",[58,59],"2017-06","2017-12","2015-02",20,[1704],"Implant Therapy",[1687],{"trials":1707,"activeCount":70},[],{"trials":1709,"activeCount":70},[],{"trials":1711,"activeCount":70},[],{"intervention":1713,"totalTrials":66,"cells":1714},"Spironolactone\u002FVitamin E",{"EARLY_PHASE1":1715,"PHASE1":1717,"PHASE2":1719,"PHASE3":1731,"PHASE4":1733,"NA":1735},{"trials":1716,"activeCount":70},[],{"trials":1718,"activeCount":70},[],{"trials":1720,"activeCount":70},[1721],{"nctId":1722,"briefTitle":1723,"status":136,"phases":1724,"primaryCompletion":1725,"completion":1726,"start":1390,"enrollment":1322,"conditions":1727,"interventions":1730},"NCT01147523","Effect of Spironolactone and Vitamin E in Patients With Nonalcoholic Fatty Liver Disease",[59],"2010-11","2011-12",[1728,1729],"Fatty Liver","Steatohepatitis",[1713],{"trials":1732,"activeCount":70},[],{"trials":1734,"activeCount":70},[],{"trials":1736,"activeCount":70},[],{"intervention":224,"totalTrials":66,"cells":1738},{"EARLY_PHASE1":1739,"PHASE1":1741,"PHASE2":1743,"PHASE3":1749,"PHASE4":1751,"NA":1753},{"trials":1740,"activeCount":70},[],{"trials":1742,"activeCount":70},[],{"trials":1744,"activeCount":70},[1745],{"nctId":215,"briefTitle":216,"status":136,"phases":1746,"primaryCompletion":218,"completion":218,"start":219,"enrollment":220,"conditions":1747,"interventions":1748},[59],[222],[224,206],{"trials":1750,"activeCount":70},[],{"trials":1752,"activeCount":70},[],{"trials":1754,"activeCount":70},[],{"intervention":1756,"totalTrials":66,"cells":1757},"BM-MSCs\u002Ffibrin glue\u002Fcollagen fleece",{"EARLY_PHASE1":1758,"PHASE1":1760,"PHASE2":1762,"PHASE3":1773,"PHASE4":1775,"NA":1777},{"trials":1759,"activeCount":70},[],{"trials":1761,"activeCount":70},[],{"trials":1763,"activeCount":70},[1764],{"nctId":1765,"briefTitle":1766,"status":136,"phases":1767,"primaryCompletion":1768,"completion":1769,"start":610,"enrollment":1322,"conditions":1770,"interventions":1772},"NCT02449005","Autologous Alveolar Bone Marrow Mesenchymal Stem Cells for the Reconstruction of Infrabony Periodontal Defects",[58,59],"2016-09","2016-12",[1771],"Chronic Periodontitis",[1756],{"trials":1774,"activeCount":70},[],{"trials":1776,"activeCount":70},[],{"trials":1778,"activeCount":70},[],{"intervention":1780,"totalTrials":66,"cells":1781},"Platelet Rich Plasma",{"EARLY_PHASE1":1782,"PHASE1":1784,"PHASE2":1797,"PHASE3":1799,"PHASE4":1801,"NA":1803},{"trials":1783,"activeCount":70},[],{"trials":1785,"activeCount":70},[1786],{"nctId":1787,"briefTitle":1788,"status":136,"phases":1789,"primaryCompletion":1790,"completion":1791,"start":83,"enrollment":696,"conditions":1792,"interventions":1796},"NCT07456215","The Effect of Platelet Rich Plasma (PRP) Application on Rotator Cuff Tear.",[58],"2026-01-13","2026-01-14",[1793,1794,1795],"Tendon Injuries","Supraspinatus Injury","PRP",[1780],{"trials":1798,"activeCount":70},[],{"trials":1800,"activeCount":70},[],{"trials":1802,"activeCount":70},[],{"trials":1804,"activeCount":70},[],{"intervention":1806,"totalTrials":66,"cells":1807},"Corticosteroids",{"EARLY_PHASE1":1808,"PHASE1":1817,"PHASE2":1819,"PHASE3":1821,"PHASE4":1823,"NA":1825},{"trials":1809,"activeCount":70},[1810],{"nctId":1811,"briefTitle":1812,"status":172,"phases":1813,"primaryCompletion":1027,"completion":139,"start":1390,"enrollment":696,"conditions":1814,"interventions":1816},"NCT01231009","The Role of Corticosteroids and Vestibular Exercises in Recovery of Vestibular Neuritis",[57],[1815],"Vestibular Neuritis",[1806],{"trials":1818,"activeCount":70},[],{"trials":1820,"activeCount":70},[],{"trials":1822,"activeCount":70},[],{"trials":1824,"activeCount":70},[],{"trials":1826,"activeCount":70},[],{"intervention":1506,"totalTrials":34,"cells":1828},{"EARLY_PHASE1":1829,"PHASE1":1831,"PHASE2":1833,"PHASE3":1835,"PHASE4":1837,"NA":1847},{"trials":1830,"activeCount":70},[],{"trials":1832,"activeCount":70},[],{"trials":1834,"activeCount":70},[],{"trials":1836,"activeCount":70},[],{"trials":1838,"activeCount":70},[1839,1843],{"nctId":1361,"briefTitle":1362,"status":136,"phases":1840,"primaryCompletion":1364,"completion":567,"start":1365,"enrollment":568,"conditions":1841,"interventions":1842},[61],[1367],[1369,1370,1348],{"nctId":1497,"briefTitle":1498,"status":172,"phases":1844,"primaryCompletion":1500,"completion":1501,"start":854,"enrollment":1502,"conditions":1845,"interventions":1846},[61],[21,1504],[1484,1506],{"trials":1848,"activeCount":70},[1849,1860],{"nctId":1850,"briefTitle":1851,"status":136,"phases":1852,"primaryCompletion":1853,"completion":1853,"start":1854,"enrollment":1855,"conditions":1856,"interventions":1859},"NCT05572749","Clinical Trial of Crocus Kozanis Administration in Obese Children and Adolescents",[62],"2023-09-30","2021-05-01",75,[1857,29,1858],"PreDiabetes","Dyslipidemias",[1506],{"nctId":1861,"briefTitle":1862,"status":136,"phases":1863,"primaryCompletion":305,"completion":524,"start":1864,"enrollment":1865,"conditions":1866,"interventions":1871},"NCT00636766","Diagnosis and Therapy of Vulnerable Atherosclerotic Plaque",[62],"2005-09",300,[1867,1868,1869,1870],"Carotid Atherosclerosis","Stroke","Type 2 Diabetes","Metabolic Syndrome",[1872,1873,1369,1370],"atorvastatin","rimonabant",{"intervention":1369,"totalTrials":1875,"cells":1876},3,{"EARLY_PHASE1":1877,"PHASE1":1879,"PHASE2":1881,"PHASE3":1883,"PHASE4":1885,"NA":1900},{"trials":1878,"activeCount":70},[],{"trials":1880,"activeCount":70},[],{"trials":1882,"activeCount":70},[],{"trials":1884,"activeCount":70},[],{"trials":1886,"activeCount":70},[1887,1891],{"nctId":1361,"briefTitle":1362,"status":136,"phases":1888,"primaryCompletion":1364,"completion":567,"start":1365,"enrollment":568,"conditions":1889,"interventions":1890},[61],[1367],[1369,1370,1348],{"nctId":1892,"briefTitle":1893,"status":136,"phases":1894,"completion":1895,"start":1365,"enrollment":568,"conditions":1896,"interventions":1898},"NCT00306176","Rosiglitazone and Exercise in Patients With Type 2 Diabetes Mellitus",[61],"2006-10",[1897],"Type II Diabetes Mellitus",[1899],"Rosiglitazone",{"trials":1901,"activeCount":70},[1902],{"nctId":1861,"briefTitle":1862,"status":136,"phases":1903,"primaryCompletion":305,"completion":524,"start":1864,"enrollment":1865,"conditions":1904,"interventions":1905},[62],[1867,1868,1869,1870],[1872,1873,1369,1370],{"intervention":1872,"totalTrials":9,"cells":1907},{"EARLY_PHASE1":1908,"PHASE1":1910,"PHASE2":1912,"PHASE3":1914,"PHASE4":1916,"NA":1918},{"trials":1909,"activeCount":70},[],{"trials":1911,"activeCount":70},[],{"trials":1913,"activeCount":70},[],{"trials":1915,"activeCount":70},[],{"trials":1917,"activeCount":70},[],{"trials":1919,"activeCount":70},[1920,1924],{"nctId":1861,"briefTitle":1862,"status":136,"phases":1921,"primaryCompletion":305,"completion":524,"start":1864,"enrollment":1865,"conditions":1922,"interventions":1923},[62],[1867,1868,1869,1870],[1872,1873,1369,1370],{"nctId":1925,"briefTitle":1926,"status":136,"phases":1927,"primaryCompletion":1928,"start":567,"enrollment":1573,"conditions":1929,"interventions":1931},"NCT01126684","Effects of Atorvastatin on Blood Pressure and Urinary Albumin Excretion",[62],"2009-12",[21,1930],"Hypercholesterolemia",[1932],"Atorvastatin",{"intervention":1934,"totalTrials":66,"cells":1935},"Mechanical Treatment",{"EARLY_PHASE1":1936,"PHASE1":1938,"PHASE2":1940,"PHASE3":1942,"PHASE4":1944,"NA":1946},{"trials":1937,"activeCount":70},[],{"trials":1939,"activeCount":70},[],{"trials":1941,"activeCount":70},[],{"trials":1943,"activeCount":70},[],{"trials":1945,"activeCount":70},[],{"trials":1947,"activeCount":70},[1948],{"nctId":1949,"briefTitle":1950,"status":136,"phases":1951,"primaryCompletion":1952,"completion":1952,"start":1953,"enrollment":1702,"conditions":1954,"interventions":1956},"NCT05733234","Lasers in Peri-implantitis Treatment",[62],"2022-03-21","2021-05-20",[1955],"Peri-Implantitis",[1934],{"intervention":145,"totalTrials":66,"cells":1958},{"EARLY_PHASE1":1959,"PHASE1":1961,"PHASE2":1963,"PHASE3":1965,"PHASE4":1967,"NA":1969},{"trials":1960,"activeCount":70},[],{"trials":1962,"activeCount":70},[],{"trials":1964,"activeCount":70},[],{"trials":1966,"activeCount":70},[],{"trials":1968,"activeCount":70},[],{"trials":1970,"activeCount":70},[1971],{"nctId":134,"briefTitle":135,"status":136,"phases":1972,"primaryCompletion":138,"completion":139,"start":140,"enrollment":141,"conditions":1973,"interventions":1974},[62],[143],[45,145],{"intervention":1976,"totalTrials":66,"cells":1977},"Empagliflozin10Mg Tab",{"EARLY_PHASE1":1978,"PHASE1":1980,"PHASE2":1982,"PHASE3":1984,"PHASE4":1986,"NA":1988},{"trials":1979,"activeCount":70},[],{"trials":1981,"activeCount":70},[],{"trials":1983,"activeCount":70},[],{"trials":1985,"activeCount":70},[],{"trials":1987,"activeCount":70},[],{"trials":1989,"activeCount":70},[1990],{"nctId":1991,"briefTitle":1992,"status":172,"phases":1993,"primaryCompletion":1994,"completion":1994,"start":1995,"enrollment":696,"conditions":1996,"interventions":2002},"NCT06284850","Empagliflozin and Red Blood Cell 2,3-biphosphoglycerate Levels",[],"2025-11","2023-11-30",[1997,1998,1999,2000,2001],"Hematocrit Change","Cardiovascular Prevention","Empagliflozin","SGLT2-Inhibitors","Tissue Oxygenation",[1976],{"intervention":2004,"totalTrials":66,"cells":2005},"Indocyanine Green",{"EARLY_PHASE1":2006,"PHASE1":2008,"PHASE2":2010,"PHASE3":2012,"PHASE4":2014,"NA":2016},{"trials":2007,"activeCount":70},[],{"trials":2009,"activeCount":70},[],{"trials":2011,"activeCount":70},[],{"trials":2013,"activeCount":70},[],{"trials":2015,"activeCount":70},[],{"trials":2017,"activeCount":70},[2018],{"nctId":2019,"briefTitle":2020,"status":136,"phases":2021,"primaryCompletion":2022,"completion":2022,"start":2023,"enrollment":220,"conditions":2024,"interventions":2027},"NCT03910049","Does Indocyanine Imaging Scoring Predicts Postoperative Parathormone Levels at 24 Hours After Total Thyroidectomy",[],"2019-04-26","2018-12-03",[2025,2026],"Thyroid","Parathyroid; Deficiency",[2004],{"intervention":2029,"totalTrials":66,"cells":2030},"SNPs associated with CAD",{"EARLY_PHASE1":2031,"PHASE1":2033,"PHASE2":2035,"PHASE3":2037,"PHASE4":2039,"NA":2041},{"trials":2032,"activeCount":70},[],{"trials":2034,"activeCount":70},[],{"trials":2036,"activeCount":70},[],{"trials":2038,"activeCount":70},[],{"trials":2040,"activeCount":70},[],{"trials":2042,"activeCount":70},[2043],{"nctId":2044,"briefTitle":2045,"status":172,"phases":2046,"primaryCompletion":2047,"completion":2048,"start":2049,"enrollment":6,"conditions":2050,"interventions":2053},"NCT03315234","Correlation of Genetic Polymorphisms and Clinical Parameters With the Complexity of Coronary Artery Disease",[],"2018-06-30","2021-06-30","2016-09-01",[26,2051,2052],"Cardiovascular Risk Factor","Coronary Arteriosclerosis",[2029],{"intervention":2055,"totalTrials":66,"cells":2056},"Euglyca application",{"EARLY_PHASE1":2057,"PHASE1":2059,"PHASE2":2061,"PHASE3":2063,"PHASE4":2065,"NA":2067},{"trials":2058,"activeCount":70},[],{"trials":2060,"activeCount":70},[],{"trials":2062,"activeCount":70},[],{"trials":2064,"activeCount":70},[],{"trials":2066,"activeCount":70},[],{"trials":2068,"activeCount":70},[2069],{"nctId":2070,"briefTitle":2071,"status":136,"phases":2072,"primaryCompletion":2073,"completion":2073,"start":2074,"enrollment":236,"conditions":2075,"interventions":2077},"NCT03763474","Euglyca Application in Children and Adolescents With Type 1 Diabetes Mellitus",[62],"2018-09-01","2017-04-01",[2076],"Diabetes Mellitus, Type 1",[2055],{"intervention":2079,"totalTrials":66,"cells":2080},"Real time PCR",{"EARLY_PHASE1":2081,"PHASE1":2083,"PHASE2":2085,"PHASE3":2087,"PHASE4":2089,"NA":2091},{"trials":2082,"activeCount":70},[],{"trials":2084,"activeCount":70},[],{"trials":2086,"activeCount":70},[],{"trials":2088,"activeCount":70},[],{"trials":2090,"activeCount":70},[],{"trials":2092,"activeCount":70},[2093],{"nctId":2094,"briefTitle":2095,"status":136,"phases":2096,"primaryCompletion":2097,"completion":2098,"start":2099,"enrollment":2100,"conditions":2101,"interventions":2106},"NCT03433768","Androgen Receptor mRNA Expression is Positively Associated With Live Birth in Women Undergoing IVF Independently of the Type of Ovarian Response",[],"2017-10-10","2018-01-10","2014-09-14",67,[2102,2103,2104,2105],"Androgen Receptor Gene Overexpression","Normal Responders","Poor Ovarian Response","Bologna Criteria",[2079],{"intervention":2108,"totalTrials":66,"cells":2109},"Desflurane",{"EARLY_PHASE1":2110,"PHASE1":2112,"PHASE2":2114,"PHASE3":2116,"PHASE4":2118,"NA":2120},{"trials":2111,"activeCount":70},[],{"trials":2113,"activeCount":70},[],{"trials":2115,"activeCount":70},[],{"trials":2117,"activeCount":70},[],{"trials":2119,"activeCount":70},[],{"trials":2121,"activeCount":70},[2122],{"nctId":2123,"briefTitle":2124,"status":136,"phases":2125,"primaryCompletion":2047,"completion":2047,"start":2126,"enrollment":2127,"conditions":2128,"interventions":2130},"NCT03848780","Desflurane Preconditioning in Hepatectomies",[62],"2016-04-01",46,[2129],"Ischemia Reperfusion Injury",[2108],{"intervention":2132,"totalTrials":66,"cells":2133},"Apneic oxygenation - supplemental high flow oxygen administration by an apneic way",{"EARLY_PHASE1":2134,"PHASE1":2136,"PHASE2":2138,"PHASE3":2140,"PHASE4":2142,"NA":2144},{"trials":2135,"activeCount":70},[],{"trials":2137,"activeCount":70},[],{"trials":2139,"activeCount":70},[],{"trials":2141,"activeCount":70},[],{"trials":2143,"activeCount":70},[],{"trials":2145,"activeCount":70},[2146],{"nctId":2147,"briefTitle":2148,"status":172,"phases":2149,"primaryCompletion":2150,"completion":2151,"start":2152,"enrollment":11,"conditions":2153,"interventions":2160},"NCT05028023","Tracheal Dilatation in Pediatric Patients With Acquired Tracheal Stenosis, and the Effects of Apneic Oxygenation",[62],"2022-01-31","2022-08-31","2020-10-21",[2154,2155,2156,2157,2158,2159],"Apnea+Hypopnea","Tracheal Dilatation","Igel","Tracheal Stenosis","Cerebral Hypoxia","Pediatric Respiratory Diseases",[2132],{"intervention":2162,"totalTrials":66,"cells":2163},"insulin",{"EARLY_PHASE1":2164,"PHASE1":2166,"PHASE2":2168,"PHASE3":2170,"PHASE4":2172,"NA":2174},{"trials":2165,"activeCount":70},[],{"trials":2167,"activeCount":70},[],{"trials":2169,"activeCount":70},[],{"trials":2171,"activeCount":70},[],{"trials":2173,"activeCount":70},[],{"trials":2175,"activeCount":70},[2176],{"nctId":2177,"briefTitle":2178,"status":136,"phases":2179,"primaryCompletion":2180,"completion":2180,"start":1252,"enrollment":2181,"conditions":2182,"interventions":2184},"NCT03179280","Effect of Dual-wave Insulin Bolus on Postprandial Glycaemia",[62],"2011-05",10,[2183],"Type1 Diabetes",[2162],{"intervention":1873,"totalTrials":66,"cells":2186},{"EARLY_PHASE1":2187,"PHASE1":2189,"PHASE2":2191,"PHASE3":2193,"PHASE4":2195,"NA":2197},{"trials":2188,"activeCount":70},[],{"trials":2190,"activeCount":70},[],{"trials":2192,"activeCount":70},[],{"trials":2194,"activeCount":70},[],{"trials":2196,"activeCount":70},[],{"trials":2198,"activeCount":70},[2199],{"nctId":1861,"briefTitle":1862,"status":136,"phases":2200,"primaryCompletion":305,"completion":524,"start":1864,"enrollment":1865,"conditions":2201,"interventions":2202},[62],[1867,1868,1869,1870],[1872,1873,1369,1370],{"intervention":2204,"totalTrials":66,"cells":2205},"Pregabalin group",{"EARLY_PHASE1":2206,"PHASE1":2208,"PHASE2":2210,"PHASE3":2212,"PHASE4":2214,"NA":2216},{"trials":2207,"activeCount":70},[],{"trials":2209,"activeCount":70},[],{"trials":2211,"activeCount":70},[],{"trials":2213,"activeCount":70},[],{"trials":2215,"activeCount":70},[],{"trials":2217,"activeCount":70},[2218],{"nctId":2219,"briefTitle":2220,"status":172,"phases":2221,"primaryCompletion":2222,"completion":2223,"start":2224,"enrollment":568,"conditions":2225,"interventions":2227},"NCT06252116","Study of Analgesic Action of Pregabalin, Duloxetine and Tramadol in Patients With Different Neuropathic Pain Phenotypes",[],"2024-07-20","2024-09-07","2018-03-05",[2226],"Neuropathic Pain",[2204,2228],"Duloxetine group",{"intervention":2228,"totalTrials":66,"cells":2230},{"EARLY_PHASE1":2231,"PHASE1":2233,"PHASE2":2235,"PHASE3":2237,"PHASE4":2239,"NA":2241},{"trials":2232,"activeCount":70},[],{"trials":2234,"activeCount":70},[],{"trials":2236,"activeCount":70},[],{"trials":2238,"activeCount":70},[],{"trials":2240,"activeCount":70},[],{"trials":2242,"activeCount":70},[2243],{"nctId":2219,"briefTitle":2220,"status":172,"phases":2244,"primaryCompletion":2222,"completion":2223,"start":2224,"enrollment":568,"conditions":2245,"interventions":2246},[],[2226],[2204,2228],{"intervention":2248,"totalTrials":66,"cells":2249},"mean diurnal intraocular pressure-lowering",{"EARLY_PHASE1":2250,"PHASE1":2252,"PHASE2":2254,"PHASE3":2256,"PHASE4":2258,"NA":2260},{"trials":2251,"activeCount":70},[],{"trials":2253,"activeCount":70},[],{"trials":2255,"activeCount":70},[],{"trials":2257,"activeCount":70},[],{"trials":2259,"activeCount":70},[],{"trials":2261,"activeCount":70},[2262],{"nctId":2263,"briefTitle":2264,"status":136,"phases":2265,"primaryCompletion":2266,"completion":2267,"start":2268,"enrollment":1028,"conditions":2269,"interventions":2270},"NCT04673604","From Preserved, to Preservative-free Cyclosporine 0.1% Enhanced Triple Glaucoma Therapy",[62],"2019-12-31","2020-06-29","2018-05-06",[15,858],[2248],{"intervention":2272,"totalTrials":66,"cells":2273},"Gene Polymorphisms of MMP-8",{"EARLY_PHASE1":2274,"PHASE1":2276,"PHASE2":2278,"PHASE3":2280,"PHASE4":2282,"NA":2284},{"trials":2275,"activeCount":70},[],{"trials":2277,"activeCount":70},[],{"trials":2279,"activeCount":70},[],{"trials":2281,"activeCount":70},[],{"trials":2283,"activeCount":70},[],{"trials":2285,"activeCount":70},[2286],{"nctId":2287,"briefTitle":2288,"status":136,"phases":2289,"primaryCompletion":2290,"completion":2291,"start":2292,"enrollment":568,"conditions":2293,"interventions":2294},"NCT05711407","Peri-implantitis and MMP-8",[],"2024-01-01","2025-01-01","2023-03-03",[1955],[2272],{"intervention":2296,"totalTrials":66,"cells":2297},"Ferric carboxymaltose",{"EARLY_PHASE1":2298,"PHASE1":2300,"PHASE2":2302,"PHASE3":2304,"PHASE4":2306,"NA":2308},{"trials":2299,"activeCount":70},[],{"trials":2301,"activeCount":70},[],{"trials":2303,"activeCount":70},[],{"trials":2305,"activeCount":70},[],{"trials":2307,"activeCount":70},[],{"trials":2309,"activeCount":70},[2310],{"nctId":2311,"briefTitle":2312,"status":172,"phases":2313,"primaryCompletion":2314,"completion":2315,"start":2316,"enrollment":2317,"conditions":2318,"interventions":2322},"NCT04974021","Iron Intravenous Therapy in Reducing the Burden of Severe Arrhythmias in Heart Failure With Reduced Ejection Fraction",[],"2021-08-30","2021-09-30","2019-06-20",106,[2319,2320,2321],"Ferric Carboxymaltose","Heart Failure With Reduced Ejection Fraction","Arrhythmias, Cardiac",[2296],{"intervention":2324,"totalTrials":66,"cells":2325},"Fast-acting insulin aspart",{"EARLY_PHASE1":2326,"PHASE1":2328,"PHASE2":2330,"PHASE3":2332,"PHASE4":2334,"NA":2336},{"trials":2327,"activeCount":70},[],{"trials":2329,"activeCount":70},[],{"trials":2331,"activeCount":70},[],{"trials":2333,"activeCount":70},[],{"trials":2335,"activeCount":70},[],{"trials":2337,"activeCount":70},[2338],{"nctId":2339,"briefTitle":2340,"status":136,"phases":2341,"primaryCompletion":2342,"completion":2343,"start":2344,"enrollment":8,"conditions":2345,"interventions":2347},"NCT04149262","Fiasp® Versus NovoRapid® in Children With Type 1 Diabetes on MiniMed 640G Pump With Sensor",[],"2020-03-31","2023-02-15","2019-11-15",[2346],"Type 1 Diabetes",[2324,2348],"Rapid-acting insulin analogues",{"intervention":2348,"totalTrials":66,"cells":2350},{"EARLY_PHASE1":2351,"PHASE1":2353,"PHASE2":2355,"PHASE3":2357,"PHASE4":2359,"NA":2361},{"trials":2352,"activeCount":70},[],{"trials":2354,"activeCount":70},[],{"trials":2356,"activeCount":70},[],{"trials":2358,"activeCount":70},[],{"trials":2360,"activeCount":70},[],{"trials":2362,"activeCount":70},[2363],{"nctId":2339,"briefTitle":2340,"status":136,"phases":2364,"primaryCompletion":2342,"completion":2343,"start":2344,"enrollment":8,"conditions":2365,"interventions":2366},[],[2346],[2324,2348],{"intervention":2368,"totalTrials":66,"cells":2369},"Premixed Human Isophane Insulin Suspension + Human Insulin",{"EARLY_PHASE1":2370,"PHASE1":2372,"PHASE2":2374,"PHASE3":2376,"PHASE4":2378,"NA":2380},{"trials":2371,"activeCount":70},[],{"trials":2373,"activeCount":70},[],{"trials":2375,"activeCount":70},[],{"trials":2377,"activeCount":70},[],{"trials":2379,"activeCount":70},[],{"trials":2381,"activeCount":70},[2382],{"nctId":2383,"briefTitle":2384,"status":136,"phases":2385,"primaryCompletion":2386,"completion":2386,"start":2387,"enrollment":1596,"conditions":2388,"interventions":2390},"NCT04726657","Comparison of Two Biphasic Insulin Regimens",[62],"2020-02-03","2016-01-18",[2389],"Diabetes Mellitus, Type 2",[2368,2391],"Premixed Insulin",{"intervention":2391,"totalTrials":66,"cells":2393},{"EARLY_PHASE1":2394,"PHASE1":2396,"PHASE2":2398,"PHASE3":2400,"PHASE4":2402,"NA":2404},{"trials":2395,"activeCount":70},[],{"trials":2397,"activeCount":70},[],{"trials":2399,"activeCount":70},[],{"trials":2401,"activeCount":70},[],{"trials":2403,"activeCount":70},[],{"trials":2405,"activeCount":70},[2406],{"nctId":2383,"briefTitle":2384,"status":136,"phases":2407,"primaryCompletion":2386,"completion":2386,"start":2387,"enrollment":1596,"conditions":2408,"interventions":2409},[62],[2389],[2368,2391],{"intervention":2411,"totalTrials":66,"cells":2412},"Varenicline use for smoking cessation",{"EARLY_PHASE1":2413,"PHASE1":2415,"PHASE2":2417,"PHASE3":2419,"PHASE4":2421,"NA":2423},{"trials":2414,"activeCount":70},[],{"trials":2416,"activeCount":70},[],{"trials":2418,"activeCount":70},[],{"trials":2420,"activeCount":70},[],{"trials":2422,"activeCount":70},[],{"trials":2424,"activeCount":70},[2425],{"nctId":2426,"briefTitle":2427,"status":136,"phases":2428,"primaryCompletion":2429,"completion":2429,"start":234,"enrollment":2317,"conditions":2430,"interventions":2433},"NCT02991781","Combined Bio- and Neuro- Feedback vs. Varenicline Use for Smoking Cessation",[62],"2019-06",[2431,167,2432],"Chronic Obstructive Pulmonary Disease (COPD)","Smoking",[2411]]